VECT Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-2.100.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$1.06BSmall cap
Valuation
- Forward P/E
- —
- PEG ratio
- 0.00
- P/B
- 3.62
- P/S (TTM)
- 21.08
- EV/EBITDA
- -5.21
Profitability & growth
- ROE (TTM)
- -56.9%
- Operating margin
- -294.5%
- Revenue growth YoY
- 0.0%
- Dividend yield
- 0.0%
- Beta
- 0.10
Last earnings
Nov 29, 2023 · Estimate $-0.46 · Reported $0.00
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
40 articles · sorted by datePage 1 of 2 · 40 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About VectivBio Holding AG
Company profileVectivBio Holding AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of treatments for rare conditions. The company is headquartered in Basel, Switzerland.
Classification
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- AESCHENVORSTADT 36, BASEL, SWITZERLAND
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2023
Market cap$1.06B
Shares outstanding$62.8M
52W high$0.00
52W low$0.00
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent